Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on recrystallization. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN103739635A reveals a novel recrystallization method for 1,3,4,6-tetra-O-acetyl-beta-D-mannopyranose, significantly boosting yield and purity for reliable 18F-FDG production.
Patent CN111056939A reveals a novel recrystallization method for (1R,3S)-3-aminocyclopentanol, offering high optical purity and yield for Bictegravir synthesis.
Solve bromine impurity challenges in prucalopride synthesis. Our optimized recrystallization method achieves >99.8% purity and 93% yield, reducing supply chain risks for API manufacturers.
Solve chiral purity challenges in halichondrin synthesis with 99.7% ee and 92% yield. Reduce impurity removal burden for Eribulin mesylate production. CDMO expertise for scalable manufacturing.
Solve chiral purity challenges in halichondrin synthesis. Our CDMO expertise delivers >99% ee intermediates with 92% yield, reducing impurity risks for oncology drug development.
Solve bempedoic acid synthesis challenges with trityl-protected intermediate. 97.8% yield, no toxic reagents, scalable for GMP production.
Overcome low yield and complex purification in Favipiravir manufacturing. New one-pot method with 65% yield reduces costs and eliminates chromatography. Contact us for scalable production.
Solve impurity E risks & cost issues in 3,5-dichlorobenzyl alcohol production. New method ensures >99.9% purity, 96% yield, and eliminates warning structure impurities for pharma supply chains.
Solve impurity challenges in flunaprazan intermediate production. 99.82% HPLC purity, 0.07% max impurity, 30% cost reduction. Scale to 100 MT/yr.